Timothy Watts has over 25 years’ experience in the pharmaceutical and biotech sectors. He qualified as a chartered accountant with Coopers & Lybrand before moving to HJ Heinz. He subsequently joined ICI in 1985, initially in the corporate headquarters before moving into the ICI Pharmaceuticals Division in 1990 (subsequently spun out of ICI into Zeneca PLC) where he held a range of positions, both financial and in general management, before being appointed Finance Director of the Zeneca Pharmaceuticals business in 1998. Following Zeneca’s merger with Astra he became Group Financial Controller of AstraZeneca PLC in 2002. In 2007 Mr Watts was appointed CFO of Archimedes Pharma, a private equity backed specialty pharma company, where he served for 4 years. In February 2012 Mr Watts was appointed CFO and board member of Oxford BioMedica PLC, a leading gene and cell therapy company. He retired from Oxford BioMedica at the end of September 2017. Mr Watts is a member of the Institute of Chartered Accountants in England & Wales and the Association of Corporate Treasurers. He also was a director of the UK’s BioIndustry Association from 2013 to 2017. Mr Watts chairs the Company’s audit committee.

Alan Mawson is a venture capital fund manager, the Founder and now Non-executive Chairman of Clarendon Fund Managers Limited (“Clarendon”). He was an initial director of the General Partner of the Rainbow Seed Fund, now a £24 million fund, set up to commercialise technology arising from the UK public sector research laboratories, and of other fund management companies. A Master of Science of the Sloan School, MIT, Cambridge, Mass., a former consultant with McKinsey & Co, Director of Research at Wiggins Teape and Chair of Council of the University of Salford, Alan, an organic and polymer research chemist, joined the Fusion Antibodies as a Director in 2004 as a representative of Clarendon.

Colin Walsh is Chief Executive and founder of Crescent Capital and has been an active venture capital investor in the high-tech sector for the past twenty eight years. He has considerable experience of business strategy and governance issues, mentoring senior management plus the restructuring, growth and development of companies across many sectors. He has served on numerous boards including both as a director and chair of Andor Technology plc, an AIM listed company and Trafficmaster plc, a LSE main market listed company. A former chair of the CBI for Northern Ireland, he joined the Fusion Antibodies as a Director in 2007 as a representative of Crescent Capital. Colin is the chair of the Company’s remuneration committee.

Sonya Ferguson is an experienced senior director working in the pharmaceuticals industry. She is currently Senior Director of Q2 Solutions, a Quintiles Quest joint venture, which is a leading global clinical trials laboratory services organisation. Her previous roles include Quintiles itself and over 18 years with Randox Laboratories. Ms Ferguson joined the Company as a Director in 2016 and is a member of the Company’s remuneration committee.

James Fair has eight years’ experience working in the bioscience sector. A mathematics graduate, James qualified as a chartered accountant in 1992 having trained with a Big Four firm. He has been head of finance with Fusion Antibodies for 8 years on a secondment basis and joined the Company as a Director full time on 1 August 2017, where he is responsible for all aspects of financial management including internal and external financial reporting. He has been involved in the growth of the business and previous raisings for the Company.

James’s previous experience has included senior management positions in internal audit, business and professional practice where his recent experience was in advising and supporting start-up and spin out companies from Northern Ireland entrepreneurs and local Universities.

Richard Buick has more than 19 years’ experience in the biopharmaceutical industry. After graduating with a 1st Class Honours degree in Genetics, he spent 4 years at Randox Laboratories, discovering novel antibodies for diagnostics from synthetic libraries. Richard joined Fusion Antibodies in 2002, where he was responsible for overseeing the Company’s Contract Research Services and production of all reagents required for the research and development of internal drug assets. Richard has a PhD from Queen’s University Belfast in Immunology. He joined the Company as a Director and was appointed CTO in 2011, managing all scientific projects and Fusion Antibodies’ patent portfolios. In addition, Richard has, since 2015, been appointed as a legal expert witness in a number of drug patent dispute cases.